159 related articles for article (PubMed ID: 27532015)
1. Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma.
Ma ES; Wang CL; Wong AT; Choy G; Chan TL
Mol Cytogenet; 2016; 9():63. PubMed ID: 27532015
[TBL] [Abstract][Full Text] [Related]
2. [Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma].
Gao L; Liu Q; Shi Y; Dang H; He Q; Wang Z; Feng L; Li Y; Wang XY; Li N; Song WJ; Wang YL; Kong S; Lu J; Huang XJ; Lai YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):807-812. PubMed ID: 28641640
[TBL] [Abstract][Full Text] [Related]
3. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
4. [Application of CD138 Immunomagnetic Bead Sorting Combined with Fluorescence in Situ Hybridization in Multiple Myeloma].
Li QZ; Tan K; Liu YX; Huang H; Zhang Y; Chen HM; Chen ZZ; Zhu ZW; Yang BH; Hu GY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1496-1500. PubMed ID: 36208255
[TBL] [Abstract][Full Text] [Related]
5. [Detection of Molecular Cytogenetic Aberrations by Fluorescence in Situ Hybridization in Different Bone Marrow Samples of Multiple Myeloma].
Wang YF; Wang H; Xi LY; Liu Y; Dong F; Wang JJ; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1352-6. PubMed ID: 26524036
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.
Lu G; Muddasani R; Orlowski RZ; Abruzzo LV; Qazilbash MH; You MJ; Wang Y; Zhao M; Chen S; Glitza IC; Medeiros LJ
Arch Pathol Lab Med; 2013 May; 137(5):625-31. PubMed ID: 23627452
[TBL] [Abstract][Full Text] [Related]
7. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
[TBL] [Abstract][Full Text] [Related]
8. Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.
Lim AS; Krishnan S; Lim TH; See K; Ng YJ; Tan YM; Choo N; Lau LC; Tien SL; Ma J; Tan D
Indian J Hematol Blood Transfus; 2014 Dec; 30(4):253-8. PubMed ID: 25435723
[TBL] [Abstract][Full Text] [Related]
9. [Detection of the Cytogenetic Aberrations in Multiple Myeloma by Using Microrray Comparative Genomic Hybridization].
Wang YF; Wang H; Xi LY; Zhang ZH; Wang J; Dong F; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1389-1395. PubMed ID: 30295256
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
[TBL] [Abstract][Full Text] [Related]
12. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
[TBL] [Abstract][Full Text] [Related]
13. Superior detection rate of plasma cell FISH using FACS-FISH.
Gagnon MF; Midthun SM; Fangel JA; Schuh CM; Luoma IM; Pearce KE; Meyer RG; Ailawadhi S; Arribas MJ; Braggio E; Fonseca R; Rajkumar SV; Zepeda-Mendoza C; Xu X; Greipp PT; Timm MM; Otteson GE; Shi M; Jevremovic D; Olteanu H; Peterson JF; Ketterling RP; Kumar S; Baughn LB
Am J Clin Pathol; 2024 Jan; 161(1):60-70. PubMed ID: 37658775
[TBL] [Abstract][Full Text] [Related]
14. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
[TBL] [Abstract][Full Text] [Related]
15. A novel human multiple myeloma cell line with a 1q21 gain genetic abnormality and CKS1B overexpression.
He J; Yi K; Zhang Y; Zhang H; Hou J; Li R
Ann Transl Med; 2023 Jan; 11(2):126. PubMed ID: 36819558
[TBL] [Abstract][Full Text] [Related]
16. Genetic and immunophenotypic profile of IGH@ rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia.
Lu G; Kong Y; Yue C
Cancer Genet Cytogenet; 2010 Jan; 196(1):56-63. PubMed ID: 19963136
[TBL] [Abstract][Full Text] [Related]
17.
Hui H; Fuller KA; Eresta Jaya L; Konishi Y; Ng TF; Frodsham R; Speight G; Yamada K; Clarke SE; Erber WN
J Clin Pathol; 2023 Nov; 76(11):763-769. PubMed ID: 36113967
[TBL] [Abstract][Full Text] [Related]
18. Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells.
Kishimoto RK; de Freitas SL; Ratis CA; Borri D; Sitnik R; Velloso ED
Rev Bras Hematol Hemoter; 2016; 38(2):113-20. PubMed ID: 27208569
[TBL] [Abstract][Full Text] [Related]
19. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
[TBL] [Abstract][Full Text] [Related]
20. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
